Citadel Advisors
HBIO icon

Citadel Advisors’s Harvard Bioscience HBIO Stock Holding History

Citadel Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,150
Closed -$5.1K – 13314
2025
Q2 		$5.1K Buy
1,150
+950
+475% +$3.97K ﹤0.01% 12231
2025
Q1 		$1.13K Sell
200
-1,300
-87% -$16.6K ﹤0.01% 14163
2024
Q4 		$31.6K Buy
1,500
+1,290
+614% +$29.6K ﹤0.01% 12818
2024
Q3 		$5.65K Buy
210
+90
+75% +$2.65K ﹤0.01% 13470
2024
Q2 		$3.42K Sell
120
-100
-45% -$3.51K ﹤0.01% 13598
2024
Q1 		$9.33K Buy
+220
New +$9.89K ﹤0.01% 13509
2023
Q4 		– Sell
-140
Closed -$6.02K – 14684
2023
Q3 		$6.02K Buy
140
+120
+600% +$5.54K ﹤0.01% 13352
2023
Q2 		$1.1K Sell
20
-20
-50% -$1.1K ﹤0.01% 13988
2023
Q1 		$1.68K Buy
+40
New +$1.19K ﹤0.01% 14257

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's HBIO Position: Q1 2026 in Review

Citadel Advisors sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 4,299 shares — an estimated $28.8K sold.

Citadel Advisors first reported a position in HBIO in Q2 2013 and held it in 27 quarters. The position peaked at $537K in Q2 2022. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Citadel Advisors reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 4,299 Harvard Bioscience shares in Q1 2026, an estimated $28.8K.
  • Citadel Advisors first reported a position in Harvard Bioscience in Q2 2013 and held it in 27 quarters.
  • Citadel Advisors's Harvard Bioscience position peaked at $537K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.